Table 2. Outcomes of the immune check inhibitor cases (n=44).
| Outcomes | No. (%) |
|---|---|
| Response* | |
| CR | 0 (0.0) |
| PR | 9 (20.5) |
| SD | 11 (25.0) |
| PD | 19 (43.2) |
| NE | 5 (11.4) |
| Adverse event** | |
| Liver dysfunction | |
| Grade 4 | 1 (2.3) |
| Grade 1 | 1 (2.3) |
| Interstitial lung disease | |
| Grade 4 | |
| Grade 3 | 2 (4.5) |
| Grade 2 | 1 (2.3) |
| Pyrexia | |
| Grade 1 | 1 (2.3) |
| Hypothyroidism | |
| Grade 2 | 2 (4.5) |
| Grade 1 | 2 (4.5) |
| Adrenal failure | |
| Grade 3 | 1 (2.3) |
| Hematuria | |
| Grade 1 | 1 (2.3) |
| Thrombopenia | |
| Grade 1 | 1 (2.3) |
*, objective response rate: 20.5%, disease control rate: 45.5%; **, overlapped cases were included. CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease; NE, not evaluable.